BiotechTube
Home/Aligos Therapeutics/Julian A. Symons
JA

Julian A. Symons

Executive Vice President, Chief Scientific Officer

Aligos Therapeutics

Therapeutic Areas

HepatologyVirology

Aligos Therapeutics Pipeline

DrugIndicationPhase
Pevifoscorvir sodium (ALG-000184)Chronic Hepatitis B (CHB)Phase 2
ALG-055009Metabolic dysfunction-associated steatohepatitis (MASH)Phase 2
ALG-125755Chronic Hepatitis B (CHB)Phase 1
ALG-097558COVID-19Preclinical

Leadership Team at Aligos Therapeutics

LM
Lawrence M. Blatt
Chairman, President & Chief Executive Officer
LA
Lesley Ann Calhoun
Executive Vice President, Chief Operating Officer & Chief Financial Officer
View full Aligos Therapeutics profile